European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A Hochhaus, M Baccarani, RT Silver, C Schiffer… - Leukemia, 2020 - nature.com
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …
First-line imatinib vs second-and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis
Imatinib, the first tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia
(CML), improves overall survival (OS), but the introduction of newer TKIs requires the …
(CML), improves overall survival (OS), but the introduction of newer TKIs requires the …
Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology
MW Deininger, NP Shah, JK Altman, E Berman… - Journal of the National …, 2020 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
M Pfirrmann, M Baccarani, S Saußele, J Guilhot… - Leukemia, 2016 - nature.com
In patients with chronic myeloid leukemia (CML), first-line imatinib treatment leads to 8-year
overall survival (OS) probabilities above 80%. Many patients die of reasons unrelated to …
overall survival (OS) probabilities above 80%. Many patients die of reasons unrelated to …
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients
BACKGROUND Outcomes in patients with chronic myeloid leukemia in blast phase (CML‐
BP) are historically dismal. Herein, the authors sought to analyze the characteristics …
BP) are historically dismal. Herein, the authors sought to analyze the characteristics …
[HTML][HTML] Chronic myeloid leukemia in 2020
R Hehlmann - Hemasphere, 2020 - journals.lww.com
New insights have emerged from maturing long-term academic and commercial clinical
trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of …
trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of …
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
M Baccarani, F Castagnetti, G Gugliotta, G Rosti… - Leukemia, 2019 - nature.com
There are different BCR-ABL1 fusion genes that are translated into proteins that are different
from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute …
from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute …
Chronic myeloid leukemia, version 2.2024, nccn clinical practice guidelines in oncology
NP Shah, R Bhatia, JK Altman, M Amaya… - Journal of the National …, 2024 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …
Management of chronic myeloid leukemia in advanced phase
M Bonifacio, F Stagno, L Scaffidi, M Krampera… - Frontiers in …, 2019 - frontiersin.org
Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …
[PDF][PDF] Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence.
R Çiftçiler, IC Haznedaroglu - European Review for Medical & …, 2021 - europeanreview.org
Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is a neoplastic
hematologic disorder, which is a functionally curable chronic disease via using tyrosine …
hematologic disorder, which is a functionally curable chronic disease via using tyrosine …